When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...

Most people with asthma are able to control their symptoms by using inhaled medicines each day. But for some people with severe asthma, inhaled medicines are not enough to keep symptoms under control.

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

Most people with a condition known as chronic rhinosinusitis with nasal polyps (CRSwNP) are able to control their symptoms by using medicines that are sprayed into the nose or taken by mouth. But some ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Results from the pivotal LIBERTY-AFRS-AIMS phase 3 study evaluating the investigational use of Dupixent in adults and ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, fulfilling that goal will hinge on its uptake in chronic obstructive pulmonary ...

Please provide your email address to receive an email when new articles are posted on . These studies are the first published using Dupixent in this indication. The primary endpoint was met by up to ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. Friday, Sanofi reported that Dupixent had set a ...